Kirsten E Lyke1. 1. Division of Malaria Research, Center for Vaccine Development, Institute for Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Great progress has been made in reducing malaria morbidity and mortality, yet the parasite continues to cause a startling 200 million infections and 500 000 deaths annually. Malaria vaccine development is pushing new boundaries by steady advancement toward a licensed product. RECENT FINDINGS: Despite 50 years of research, the complexity of Plasmoidum falciparum confounds all attempts to eradicate the organism. This very complexity has pushed the boundaries of vaccine development to new heights, yet it remains to be seen if an affordable vaccine can provide durable and high-level protection. Novel vaccines such as RTS,S/AS01E are on the edge of licensure, but old techniques have resurged with the ability to deliver vialed, whole organism vaccines. Novel adjuvants, multistage/multiantigen approaches and transmission blocking vaccines all contribute to a multipronged battle plan to conquer malaria. SUMMARY: Vaccines are the most cost-effective tools to control infectious diseases, yet the complexity of malaria has frustrated all attempts to develop an effective product. This review concentrates on recent advances in malaria vaccine development that lend hope that a vaccine can be produced and malaria eradicated.
PURPOSE OF REVIEW: Great progress has been made in reducing malaria morbidity and mortality, yet the parasite continues to cause a startling 200 million infections and 500 000 deaths annually. Malaria vaccine development is pushing new boundaries by steady advancement toward a licensed product. RECENT FINDINGS: Despite 50 years of research, the complexity of Plasmoidum falciparum confounds all attempts to eradicate the organism. This very complexity has pushed the boundaries of vaccine development to new heights, yet it remains to be seen if an affordable vaccine can provide durable and high-level protection. Novel vaccines such as RTS,S/AS01E are on the edge of licensure, but old techniques have resurged with the ability to deliver vialed, whole organism vaccines. Novel adjuvants, multistage/multiantigen approaches and transmission blocking vaccines all contribute to a multipronged battle plan to conquer malaria. SUMMARY: Vaccines are the most cost-effective tools to control infectious diseases, yet the complexity of malaria has frustrated all attempts to develop an effective product. This review concentrates on recent advances in malaria vaccine development that lend hope that a vaccine can be produced and malaria eradicated.
Authors: Eric Rogier; Doug Nace; Pedro R Dimbu; Brian Wakeman; Jan Pohl; James G Beeson; Chris Drakeley; Kevin Tetteh; Mateusz Plucinski Journal: Front Immunol Date: 2021-03-02 Impact factor: 7.561
Authors: Michelle K Muthui; Eizo Takashima; Brian R Omondi; Christine Kinya; William I Muasya; Hikaru Nagaoka; Kennedy W Mwai; Benedict Orindi; Juliana Wambua; Teun Bousema; Chris Drakeley; Andrew M Blagborough; Kevin Marsh; Philip Bejon; Melissa C Kapulu Journal: Front Cell Infect Microbiol Date: 2021-11-12 Impact factor: 5.293